Neurelis Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Neurelis Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011852
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Neurelis Inc. (Neurelis) is a specialty pharmaceutical company, which develops medicines to target unmet medical need in epilepsy and acute anxiety episodes. The company’s product portfolio includes NRL-1 (intranasal diazepam), a proprietary formulation, for epilepsy in pediatric and adult patients who need to use diazepam sporadically to control bouts of acute repetitive seizures; NRL-2 (intranasal lorazepam), which gets absorbed rapidly through a nasal spray, providing swift clinical response. Neurelis obtained Orphan drug designation for NRL-1 from the FDA for the treatment of acute repetitive seizures. The company also licenses, develops, and commercializes product candidates for the broader central nervous system (CNS) market. Neurelis is headquartered in San Diego, California.

Neurelis Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurelis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurelis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurelis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurelis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Neurelis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurelis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Neurelis Raises Funds through Series B Venture Financing 10
Neurelis Raises Funds in Series A Financing Round 11
Neurelis Secures US$1.08 Million In Venture Financing 12
Neurelis Inc – Key Competitors 13
Neurelis Inc – Key Employees 14
Neurelis Inc – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Product Approvals 16
Jan 04, 2017: Neurelis Intranasal Diazepam Treatment For Epilepsy Granted Fast Track Designation By FDA 16
Jan 19, 2016: Neurelis Initiates Pivotal Clinical Program for NRL-1 in the Treatment of Acute Repetitive Seizures 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Neurelis Inc, Pharmaceuticals & Healthcare, Key Facts 2
Neurelis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Neurelis Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Neurelis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Neurelis Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Neurelis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Neurelis Raises Funds through Series B Venture Financing 10
Neurelis Raises Funds in Series A Financing Round 11
Neurelis Secures US$1.08 Million In Venture Financing 12
Neurelis Inc, Key Competitors 13
Neurelis Inc, Key Employees 14

★海外企業調査レポート[Neurelis Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • David Lloyd Leisure Ltd:企業の戦略・SWOT・財務情報
    David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report Summary David Lloyd Leisure Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Graphic Packaging Holding Company:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Graphic Packaging Holding Compa …
  • Grupo Kuo, S.A.B de C.V. (KUOB):企業の財務及び戦略的SWOT分析
    Summary Grupo Kuo, S.A.B de C.V. (Grupo Kuo) formerly DESC, SAB de CV is a commercial holding company that develops and exports its own technologies. Its products include brake shoe, brake pads, air brake block and off-highway and industrial products; synthetic rubber emulsions; aftermarket pistons …
  • Nippon Valqua Industries Ltd.の企業概要及び財務/SWOT分析
    Nippon Valqua Industries Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Nippon Valqua Industries Ltd. annual and quarterly forecasts made by stock market experts. The r …
  • RxElite, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' RxElite, Inc. Mergers and Acqui …
  • Centrais Eletricas de Santa Catarina S.A. (CLSC4):企業の財務・戦略的SWOT分析
    Centrais Eletricas de Santa Catarina S.A. (CLSC4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Alfresa Holdings Corp (2784):企業のM&A・提携動向(医療分野)
    Summary Alfresa Holdings Corp (Alfresa) is a pharmaceutical company that manufactures and markets diagnostic reagent and medical devices. The company’s business includes ethical pharmaceuticals wholesaling, self-medication products and manufacturing. It’s ethical pharmaceutical wholesaling business …
  • Puretech Health plc (PRTC):企業の財務・戦略的SWOT分析
    Summary Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug ca …
  • General Electric Company:戦略・SWOT・企業財務分析
    General Electric Company - Strategy, SWOT and Corporate Finance Report Summary General Electric Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CANCOM SE (formerly CANCOM IT Systeme AG):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' CANCOM SE (formerly CANCOM IT S …
  • Millar Instruments, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Millar Instruments, Inc. Merger …
  • Apricus Biosciences, Inc. (formerly NexMed, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Apricus Biosciences, Inc. (form …
  • Havas SA:企業のM&A・提携・投資分析
    Havas SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Havas SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • National Fertilizers Limited (NFL):企業の財務及び戦略的SWOT分析
    Summary National Fertilizers Limited (NFL) is a chemical company that manufactures urea and bio-fertilizers. The company’s products include Kisan urea, Neem coated urea, bio-fertilizers, industrial products and traded products. It offers bio-fertilizer such as nitrogenbio-fertilizer and phosphorous …
  • Desktop Genetics Ltd:企業のM&A・提携動向(医療機器分野)
    Summary Desktop Genetics Ltd (DeskGen) offers a versatile genome editing platform to life scientists. Its product includes DESKGEN, a software system which helps scientists to organize, optimize, and automate their research. The company allows scientists to design their genome editing experiments in …
  • AxoGen, Inc. (AXGN):企業概要、財務及び戦略的SWOT分析
    Summary AxoGen, Inc (AxoGen) is a medical technology company. The company provides solutions to repair and protect peripheral nerves. Its products include Avance never graft, AxoGuard nerve Connector and AxoGuard never protector. The company also focuses on the science, development and commercializa …
  • Ligand Pharmaceuticals Inc (LGND):製薬・医療:M&Aディール及び事業提携情報
    Summary Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company employs research technologies including nuclear receptor assays, formulation science, high throughput computer screening, antibody discovery technologies an …
  • Energy Developments Limited (ENE):企業概要、財務及び戦略的SWOT分析
    Summary Energy Developments Limited (Energy Developments) is an energy service provider. The company develops, finances, designs, constructs, operates and maintains international small scale power-generating and energy delivery projects. It provides services in remote energy, LNG and CNG, landfill g …
  • BellBrook Labs:(医療機器分野)企業M&A及び提携動向
    Summary BellBrook Labs (BellBrook) is a pharmaceutical company. The company develops and distributes test kits and other devices. Its products include Transcreener HTS assays, ADP² assays, AMP²/GMP² assays, GDP assays, UDP² assays, EPIGEN methyltransferase assay, enzymes and assay kits, transzyme me …
  • Windtree Therapeutics Inc (WINT)-医療機器分野:企業M&A・提携分析
    Summary Windtree Therapeutics Inc (Windtree Therapeutics), formerly Discovery Laboratories, Inc. is a specialty biotechnology company. It focuses on the development of novel KL4 surfactant therapies for patients with respiratory diseases and other potential applications. The company’s lead developme …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆